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Abstract
Considerable evidence exists for marked beneficial
effects of omega-3 long-chain polyunsaturated fatty
acids (LC-PUFA) during pregnancy. The omega-3 LC-
PUFA docosahexaenoic acid (DHA) is incorporated in
large amounts in fetal brain and other tissues during the
second half of pregnancy, and several studies have pro-
vided evidence for a link between early DHA status of the
mother and visual and cognitive development of her child
after birth. Moreover, the supplementation of omega-3
LC-PUFA during pregnancy increases slightly infant size
at birth, and significantly reduces early preterm birth
before 34 weeks of gestation by 31%. In our studies
using stable isotope methodology in vivo, we demon-
strated active and preferential materno-fetal transfer of
DHA across the human placenta and found the expres-
sion of human placental fatty acid binding and transport
proteins. From the correlation of DHA values with pla-
cental fatty acid transport protein 4 (FATP 4), we con-
clude that this protein is of key importance in mediating
DHA transport across the human placenta. Given the
great importance of placental DHA transport for infant
outcome, further studies are needed to fully appreciate
the effects and optimal strategies of omega-3 fatty acid
interventions in pregnancy, dose response relationships,
and the potential differences between subgroups of sub-
jects such as women with gestational diabetes or other
gestational pathology. Such studies should contribute to
optimize substrate intake during pregnancy and lactation
that may improve pregnancy outcome as well as fetal
growth and development.
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Introduction
Evidence accumulates that the supply and metabolism
of long-chain polyunsaturated fatty acids (LC-PUFA) dur-
ing pregnancy is not only of importance to the pregnant
woman and to the outcome of her pregnancy, but also
to growth and tissue development of the fetus and to the
early development of the nervous system. The LC-PUFA
arachidonic (AA, 22:4 n-6) and docosahexaenoic acid
(DHA, 22:6 n-3) are preferentially deposited in relatively
high concentrations in developing neural cells, and they
modulate the structure, fluidity and function of brain
membranes w10x. The importance of brain DHA is mainly
related to its significant roles in maintaining neurological
and visual development. Decreased DHA contents in
brain and retina lipids result in altered visual acuity, dis-
turbance in electroretinographic measurements and
learning impairment in various species w10x. AA is a major
component of structural phospholipids and serves as
precursor for eicosanoids, which play important roles in
cell division, signal transduction and many other physio-
logic processes w10x. In preterm babies the availability of
AA has been associated with weight at birth and growth
during the first year of life w9x. In this paper we discuss
the potential roles of LC-PUFA supplementation during
pregnancy in perspective of preventive nutrition and their
relevance for the early development of fetus and infants.
The metabolism and tissue accretion of LC-PUFA in fetal
brain and other tissues, the mechanisms involved in their
placental transfer from mothers to their babies, and their
effects on pregnancy outcomes and development of
visual and other neural functions in newborns are
addressed in this review.
LC-PUFA supply and metabolism in the
perinatal period
LC-PUFA of the omega-6 (n-6) and omega-3 (n-3) series
are derived from the essential fatty acid precursors lino-
leic acid (n-6) and a-linolenic acid (n-3) by consecutive
enzymatic desaturation and chain elongation (Figure 1).
LC-PUFA are incorporated in practically all tissues of the
fetus and infant, and they are the predominant PUFA in
mammalian brain and neuronal tissues w25x. In humans,
most brain LC-PUFA are accumulated during the phase
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Figure 1 Metabolism of the essential fatty acids linoleic acid (18:2 n-6) and linolenic acid (18:3 n-3) to long-chain polyunsaturated
fatty acids (LC-PUFA).
of rapid brain growth in the last trimester of gestation and
the first two years after birth. Lipids are transferred
across the placenta to meet fetal demands, including the
essential fatty acids linoleic (LA, C18:2 n-6) and a-lino-
lenic acid (ALA, C18:3 n-3), as well as LC-PUFA w10x.
The fetus needs to receive appreciable amounts of
preformed AA and DHA by placental transfer to meet LC-
PUFA accretion rates in membrane rich tissues. In adults,
AA and DHA can be synthesized to a limited extent,
mainly in the liver by desaturation and elongation of the
essential fatty acids linoleic and a-linolenic acid, respec-
tively. However, the high needs in the perinatal period
cannot be met by endogenous formation of LC-PUFA
from the essential fatty acid precursors due to low activ-
ities of the desaturating enzymes in the fetus, placenta
and in newborn infants. Thus, the fetus depends on LC-
PUFA provision by placental transfer w10x.
The accumulation of brain DHA and AA from dietary
preformed DHA and AA is far more efficient than from
dietary essential fatty acid precursors and their endoge-
nous desaturation and elongation. It is estimated that
about half of postnatal brain AA accretion is derived from
dietary preformed AA in term baboon neonates w25x,
while fetal plasma DHA is about 8–20-fold more effective
as a substrate for brain DHA accretion in fetal baboons
compared with ALA w22x. In humans the fetal and infant
brain DHA content is relatively more affected by the diet
than AA content, suggesting that endogenous metabolic
regulation of AA contents is more effective w14x. Fetal tis-
sue contents of LC-PUFA depend on maternal intake and
on adequate placental transport.
Placental transfer of fatty acids
Numerous studies reported that LC-PUFA contents in
cord plasma lipids are higher than in maternal plasma
lipids at the time of birth w1x, while contents of the parent
essential fatty acids (EFA) are lower in infant than in
maternal plasma lipids. These observations point to a
preferential transfer of these fatty acids by the placenta.
Recently, we demonstrated active materno-fetal transfer
of LCPUFA using stable isotope techniques. Fatty acids
labeled with the natural carbon variant 13C were admin-
istrated 4 h before elective cesarean section to pregnant
women (Figure 2). Analysis of placental tissue at the time
of birth indicated preferential incorporation of DHA rela-
tive to linoleic acid, oleic acid and palmitic acid, thus,
demonstrating for the first time a preferential materno-
fetal DHA transfer across the human placenta in vivo (Fig-
ure 3) w11x.
The placental transfer of fatty acids is considered a
complex process, which involves binding to membrane
proteins and cytoplasmatic transport proteins w5x. It is
known that placental uptake of circulating non-esterified
fatty acids (NEFA) as well as NEFA released from mater-
nal circulating triglycerides by placental lipoprotein lip-
ase; in addition, human placental tissue expresses
receptors to VLDL, LDL and HDL lipoproteins w16x, which
could provide fatty acids to the placenta for fetal transfer
once they are released by phospholipase-A2 and intra-
cellular lipases (Figure 4), although the significance of the
latter mechanism is still unknown.
Unesterified fatty acids enter placental cells through
passive diffusion as well as through a complex, satura-
ble, protein-mediated mechanism. This transport mech-
anism seems to involve plasma membrane fatty-acid
binding protein (FABPpm/GOT2), fatty acid translocase
(FAT/CD36), fatty acid transport proteins (FATP), and fatty
acid binding proteins (FABP) (Figure 5) w5x. Although the
roles of these proteins in placental fatty acid uptake and
metabolism are not yet fully understood, it has been sug-
gested that the enrichment of LC-PUFA in the fetal cir-
culation is achieved via a complex interaction of these
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Figure 2 In vivo investigation of materno-fetal transfer of fatty acids with stable isotope techniques. Fatty acids labeled with the
natural carbon variant 13C are administrated 4 h before elective cesarean section to pregnant women. Enrichment of fatty acids is
determined from maternal blood samples taken at hourly intervals, and from placental tissue and cord blood (drawn after data of
w11x).
Figure 3 Results of in vivo investigation of materno-fetal trans-
fer of 13C-labeled fatty acids demonstrate preferential transfer of
the omega-3 long-chain polyunsaturated fatty acid DHA (doco-
sahexaenoic acid). The ratio between labeled fatty acids (fatty
acid concentration in wmmol/gx=atom percent enrichment) in
placenta and maternal plasma 4 h after tracer administration is
similar for saturated (palmitic acid, PA), monounstaurated (oleic
acid, OA) and precursor essential fatty acids (linoliec acid, LA),
but markedly higher for DHA (drawn after data of w11x).
proteins. A new fatty acid binding protein located exclu-
sively on the maternal-facing membranes named placen-
tal plasma membrane fatty acid-binding protein
(p-FABPpm) has been proposed to be involved in this pref-
erential uptake of LC-PUFA by these cells. However,
definitive evidence about the structure and function of
p-FABPpm must await analysis of its complete amino
acid and/or cDNA sequence.
In the cytosol, fatty acids are esterified within the lipid
fractions of the placenta or cross the tissue in either
direction bound to cytosolic proteins w5x. A family of pro-
teins named fatty-acid binding proteins (FABP) are
involved in the transfer to the fetal circulation. Two forms
of FABP have been identified up to the present time in
placenta: heart-FABP (H-FABP) and liver-FABP (L-FABP)
(Figure 5) w5x. However, the mRNA expression of other
cytosolic FABPs described in other tissues might occur
in placental tissue as well. This potentiality should be
confirmed in trophoblast cells since placenta samples
contain many cell types including a large content of
blood cells.
In a double-blind randomized intervention trial sup-
ported by the European Commission, the NUHEAL study,
healthy pregnant women received during the second half
of gestation supplements with modified fish oil providing
500 mg DHA per day with vitamins, or a placebo oil with
vitamins. In a group of 136 study participants, the mRNA
expression of the membrane proteins FATP-1 and partic-
ularly of FATP-4 in placental tissue were positively corre-
lated with the uptake of maternal DHA into placental and
cord blood phospolipids. These results point to a prob-
ably very important role of placental FATP-1 and FATP-4
for selective materno-fetal DHA transport in humans w12x.
LC-PUFA accretion in complicated pregnancies
A better understanding of the mechanisms involved in
the placental transfer of LC-PUFA to the neonate is of
importance in order to improve fetal DHA status not only
in uncomplicated pregnancies but also in disorders asso-
ciated with poor DHA status, such as gestational dia-
betes mellitus w24x or intrauterine growth restriction
(IUGR) babies w2x.
In gestational diabetes mellitus, low LC-PUFA contents
were found in erythrocyte and plasma phospholipids of
the babies despite normal plasma AA and DHA levels in
the mothers w24x. In addition, fetuses with IUGR have a
lower proportion of AA and DHA in fetal blood in com-
parison with maternal blood as compared to control
infants who are appropriate for gestational age w2x. Thus,
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Figure 4 Placental lipid transfer. Triglycerides (TG) from TG rich lipoproteins are hydrolyzed by liporprotein lipase. Free fatty acids
(FFA) may be transferred by passive diffusion as well as facilitated transport mediated by fatty acid transfer proteins (FATP), fatty
acid translocase (FAT) and placental membrane fatty acid binding protein (FABPpm). In addition, recepter mediated uptake of lipo-
proteins and lipid release by phosholipase A2 and other lipases may provide lipids to the placenta.
Figure 5 Placental transfer of free fatty acids (FFA) appears to be facilitated by placental fatty acid binding protein-plasmamembrane
(p-FABPpm), fatty acid translocase (FAT), fatty acid transport proteins (FATP), heart-fatty acid binding protein (H-FABP) and liver-fatty
acid binding protein (L-FABP) (modified from a scheme suggested by Dutta Roy 2000).
a greater risk for restricted LC-PUFA supply may occur
in pregnancies that are complicated with abnormal pla-
cental function affecting nutrient transfer.
The supply of preformed LC-PUFA during pregnancy
or after birth could contribute to reduce the abnormalities
in neurodevelopment observed in these babies. Enhanc-
ed DHA and AA formation was found in neonates with
low gestational age and birth weight, suggesting that
immature infants with adequate fetal growth have greater
LC-PUFA formation from EFA precursors. However, such
compensatory mechanism does not occur in infants with
IUGR in whom the final biosynthetic pathway that leads
to the synthesis of DHA is impaired w13x. Several clinical
studies have shown the benefits of DHA supplementation
in visual function of premature infants along with better
DHA status in red blood cells and plasma w10x. Thus,
targeted supplementation with LC-PUFA in pregnancies
and infants with affected DHA metabolism is a major
challenge to be addressed in the future.
An improved maternal n-3 LC-PUFA status by die-
tary intervention during pregnancy may enhance the
availability of n-3 LC-PUFA to the fetus and the infant.
Decsi and Koletzko w4x reviewed the human trials on the
potential effects of different levels on n-3 fatty acid sup-
ply in pregnancy published from December 2002 to Sep-
tember 2004 and concluded that supplementation of ALA
in a high dose ()10 g day) or DHA in a low dose
(200 mg/day) did not result in significant enhancement of
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the contribution offspring. In contrast, supplementation
of DHA in relatively high dose ()1 g/day) led to a signif-
icant increase in infantile DHA values in some studies.
LC-PUFA supply and pregnancy outcomes
Some, but not all studies, have shown that maternal
intake of fish, fish oils and n-3 LC-PUFA result in a slight-
ly longer duration of gestation and a somewhat higher
birth weight (reviewed by Olsen, 2004 w19x and Decsi and
Koletzko, 2005 w4x). It has been suggested that the
effects of n-3 fatty acids on duration of pregnancy might
meet a saturation point, above which no further effect on
LC-PUFA n-3 can be detected, and also that they may
have rapid effects, suggesting a potential use as an adju-
vant to the treatment of preterm labor w8, 19x. In the USA
the cohort study ‘‘VIVA’’ that collected data from 2109
pregnant women, a modest decrease in fetal growth was
associated with increased maternal marine n-3 PUFA
consumption during pregnancy (90 g between the lowest
and highest quartiles of intake), with no significant
changes in the length of gestation w17x. These results
should be interpreted with caution, considering the limi-
tations of observational studies which often cannot fully
adjust for all confounding variables.
Recently a meta-analysis of randomized controlled
intervention trials (RCT) was published reviewing effects
of n-3 LC-PUFA supplementation in women with low risk
pregnancies (1278 infants from 6 RCT) on pregnancy out-
comes w23x. The result show that n-3 LC-PUFA supple-
mentation during pregnancy may, to a small extent,
enhance pregnancy duration and head circumference,
but the mean effect is small w23x. The result of this anal-
ysis indicates that n-3 LC-PUFA supplementation may
increase the duration of pregnancy by an average of
1.6 days. Furthermore, n-3 LC-PUFA supplementation
during pregnancy was associated with a trend toward
greater growth measures at birth; however, this difference
was significant only for head circumference, with an aver-
age of 0.26 cm greater in the supplemented group, but
significance was lost on sensitivity analysis w23x.
A recent Cochrane review of 6 trials involving 2783
women receiving oral marine oil supplementation during
pregnancy also reported a mean gestation that was
2.6 days longer than women allocated to placebo or no
treatment w15x. Moreover, women in the marine oil arm
had a 31% lower risk of early preterm birth before 34
completed weeks of gestation (RR 0.69, 95% CI
0.49–0.99; 2 trials, 860 women). Birth weight was slightly
higher in infants born to women in the marine oil group
compared with controls (weight mean difference 47 g,
95% CI 1–93 g; 3 trials, 2440 women).
In a prospective cohort study from Denmark with 8729
pregnant women, low consumption of fish was a strong
risk factor for preterm delivery and low birth weight w18x.
However, no effects on the risk of preeclampsia, preterm
birth, low birthweight or small gestational age was found
by n-3 LC-PUFA supplementation during pregnancy in
the meta-analysis w23x or Cochrane evaluation w15x.
Perinatal LC-PUFA supply and infant
neurodevelopment
Whereas a large number of studies have evaluated the
influence of n-3 LC-PUFA supplementation on gestation-
al length and birth weight, only a few randomized studies
examined the effects of perinatal dietary LC-PUFA on
neurodevelopment.
Helland et al. performed a double blind randomized
study in pregnant women receiving, from the 17th–19th
week of gestation until three months after delivery, 1 g
DHA daily provided with 10 mL cod liver oil, or a placebo
oil (corn oil). Neonates with mature electroencephalog-
raphy (EEG) test on the second day of life had a higher
concentration of DHA in umbilical plasma phospholipids
than neonates with immature EEG, in agreement with a
relationship between DHA concentration and cerebral
maturation of the newborn w6x. However, no differences
were reported on EEG scores at three months of age or
the Fagan test (an indicator of infants’ cognitive function)
at 6 and 9 months of age in the babies w6x. In contrast,
at the age of four years, children who were born to moth-
ers who had taken cod liver oil (n-3 LC-PUFA) during
pregnancy and lactation had significantly higher IQ val-
ues, as assessed with the Kaufman Assessment Battery
for children (K-ABC) intelligence test w7x. In addition,
Colombo et al. w3x reported in a longitudinally study,
showing that infants whose mothers had higher levels of
DHA in red blood cells at birth, had more mature devel-
opmental profiles on single-object attention measures
and more optimal performance on distractibility assess-
ments during the first two years of life w3x.
The current results show associations between early
DHA status and cognitive function in infancy and early
childhood. The participants of a recent expert workshop
on dietary fat intake during the perinatal period held with
support of the European Commission’s Directorate Gen-
eral Research recommended that pregnant and lactating
women should aim to achieving a dietary intake of n-3
LC-PUFA that supplies a DHA intake of at least 200 mg
per day. Intakes up to 1 g/day of DHA or 2.7 g/day of
n-3 LC-PUFA have been used in randomized trials with-
out occurrence of significant effects.
Conclusions
The potential of the early diet for modulation of the nor-
mal trajectory of brain development is of great interest.
Results of recent studies show an active and preferential
materno-fetal transfer of DHA across the placenta,
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:56
S10 Koletzko et al., Placental transfer of long-chain polyunsaturated fatty acids (LC-PUFA)
Article in press - uncorrected proof
apparently mediated by specific binding and transfer pro-
teins. Fish oil supplementation during pregnancy slightly
increases infant size at birth and significantly reduces
early preterm birth before 34 weeks of gestation. Several
studies provided evidence for a link between early DHA
status in the mother and cognitive development of her
child. Given the great importance of these findings, fur-
ther studies are necessary to fully appreciate the effects
and optimal strategies of omega-3 fatty acid interven-
tions in pregnancy, dose response relationships, and the
potential differences between subgroups of subjects
such as women with gestational diabetes or other ges-
tational abnormalities. Such studies should contribute to
achieving optimized substrate intakes during pregnancy
and lactation that support improved pregnancy out-
comes and fetal growth and development.
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